Perceptive Advisors LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed August 6, 2024), Perceptive Advisors LLC reported 102 stock positions worth $5.7 billion. Its top holding was Cerevel Therapeutics (CERE) at 8.0% of the portfolio, followed by Amicus Therapeutics (FOLD, 5.8%) and Iovance Biotherapeutics (IOVA, 5.0%). Compared with Q4 2023, it opened 24 new positions, sold out of 16, added to 37 and reduced 17. The biggest buy was Iovance Biotherapeutics (IOVA, shares +61%) and the biggest sale an exit from Lianbio-ADR (LIANY).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001224962
- Portfolio Value
- $5.7B (Q1 2024)
- SEC Filing
- 0001012975-24-000315 ↗ filed Aug 6, 2024
Holdings Value
Holdings 102 stocks · $5.7B
| CERE Cerevel Therapeutics Holding | 8.04% | 10,794,876 | $456.3M | Reduce -1.6% |
| FOLD Amicus Therapeutics Inc. | 5.82% | 28,057,456 | $330.5M | No change |
| IOVA Iovance Biotherapeutics Inc. | 5.03% | 19,272,991 | $285.6M | Add +60.9% |
| ACLX Arcellx Inc. | 4.82% | 3,933,556 | $273.6M | Reduce -13.4% |
| NUVL Nuvalent Inc. Class A | 3.68% | 2,783,454 | $209.0M | Reduce -4.6% |
| INHIBRX INC | 2.62% | 4,256,104 | $148.8M | No change |
| FUSN Fusion Pharmaceuticals Inc. | 2.56% | 6,825,395 | $145.5M | Add +148.1% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.50% | 3,268,579 | $141.6M | Add +51.7% |
| APGE Apogee Therapeutics Inc. | 2.41% | 2,060,395 | $136.9M | Add +12.7% |
| PCVX Vaxcyte Inc. | 2.33% | 1,932,759 | $132.0M | Add +77.6% |
| SLNO Soleno Therapeutics Inc. | 2.32% | 3,074,542 | $131.6M | No change |
| MDT Medtronic PLC | 2.20% | 1,429,563 | $124.6M | Add +46.4% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.02% | 429,953 | $114.8M | Add +184.4% |
| SWTX Springworks Therapeutics Inc. | 1.96% | 2,262,462 | $111.4M | Add +15.6% |
| NBIX Neurocrine Biosciences Inc. | 1.96% | 804,409 | $110.9M | Add +197.1% |
| SYRE Spyre Therapeutics Inc. | 1.71% | 2,556,679 | $97.0M | Reduce -1.9% |
| IMVT Immunovant Inc. | 1.69% | 2,963,212 | $95.7M | Add +27.3% |
| BHVN Biohaven Ltd. | 1.66% | 1,725,047 | $94.3M | No change |
| SLDB Solid Biosciences Inc. | 1.62% | 6,906,646 | $92.0M | Add +97.6% |
| ATXS Astria Therapeutics Inc. | 1.61% | 6,485,420 | $91.2M | Add +62.0% |
| AXSM Axsome Therapeutics Inc. | 1.55% | 1,105,341 | $88.2M | Add +6.5% |
| VKTX Viking Therapeutics Inc. | 1.44% | 994,098 | $81.5M | New |
| EOLS Evolus Inc. | 1.42% | 5,753,798 | $80.6M | Add +45.2% |
| LYRA Lyra Therapeutics Inc. | 1.40% | 12,757,562 | $79.4M | No change |
| CRGX Cargo Therapeutics Inc. | 1.36% | 3,448,004 | $77.0M | Add +0.3% |
| ITCI Intra-Cellular Therapies Inc. | 1.29% | 1,055,355 | $73.0M | Add +877.2% |
| NTRA Natera Inc. | 1.22% | 757,225 | $69.3M | Reduce -10.9% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.22% | 1,476,203 | $69.1M | Add +17.6% |
| MGTX Meiragtx Holdings PLC | 1.21% | 11,331,103 | $68.7M | No change |
| SRPT Sarepta Therapeutics Inc. | 1.20% | 525,683 | $68.1M | Add +16.3% |
| VRDN Viridian Therapeutics Inc. | 1.13% | 3,657,099 | $64.0M | Add +111.4% |
| VRNA Verona Pharma Ltd. | 1.07% | 3,761,576 | $60.5M | Reduce -2.7% |
| IRON Disc Medicine Inc. | 1.03% | 939,866 | $58.5M | Reduce -8.1% |
| CGON CG Oncology Inc. | 1.01% | 1,304,105 | $57.3M | New |
| AORT Artivion Inc. | 1.00% | 2,668,978 | $56.5M | Add +186.6% |
| APLT Applied Therapeutics Inc. | 0.96% | 8,005,000 | $54.4M | Add +96.2% |
| ARVN Arvinas Inc. | 0.90% | 1,236,603 | $51.0M | Add +249.2% |
| CELC Celcuity Inc. | 0.90% | 2,362,279 | $51.0M | Add +59.5% |
| PRAX Praxis Precision Medicines I | 0.88% | 821,589 | $50.1M | New |
| RCKT Rocket Pharmaceuticals Inc. | 0.86% | 1,801,068 | $48.5M | Add +5.5% |
| IMTX Immatics NV | 0.85% | 4,582,409 | $48.2M | Add +31.2% |
| TARS Tarsus Pharmaceuticals Inc. | 0.83% | 1,296,416 | $47.1M | No change |
| BBIO Bridgebio Pharma Inc. | 0.77% | 1,412,033 | $43.7M | Reduce -19.3% |
| ADMA Adma Biologics Inc. | 0.75% | 6,433,369 | $42.5M | No change |
| EWTX Edgewise Therapeutics Inc. | 0.75% | 2,319,646 | $42.3M | Add +317.5% |
| VRCA Verrica Pharmaceuticals Inc. | 0.74% | 7,099,182 | $42.0M | No change |
| ISRG Intuitive Surgical Inc. | 0.72% | 101,800 | $40.6M | Add +85.1% |
| XENE Xenon Pharmaceuticals Inc. | 0.68% | 892,208 | $38.4M | Reduce -18.9% |
| NAUT Nautilus Biotechnology Inc. | 0.65% | 12,594,211 | $37.0M | No change |
| AKRO Akero Therapeutics Inc. | 0.62% | 1,387,471 | $35.0M | Add +43.4% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.61% | 3,083,307 | $34.8M | New |
| LABP Landos Biopharma Inc. | 0.56% | 1,486,991 | $31.9M | No change |
| OCUL Ocular Therapeutix Inc. | 0.53% | 3,324,468 | $30.3M | New |
| TMCI Treace Medical Concepts Inc. | 0.53% | 2,304,954 | $30.1M | Add +84.3% |
| CABA Cabaletta Bio Inc. | 0.52% | 1,716,660 | $29.3M | Reduce -14.3% |
| PTGX Protagonist Therapeutics Inc. | 0.51% | 994,323 | $28.8M | Add +159.4% |
| IRTC Irhythm Holdings Inc. | 0.50% | 245,205 | $28.4M | New |
| ALDX Aldeyra Therapeutics Inc. | 0.50% | 8,593,586 | $28.1M | No change |
| AUTL Autolus Therapeutics PLC | 0.49% | 4,330,745 | $27.6M | Add +136.5% |
| ACRV Acrivon Therapeutics Inc. | 0.38% | 3,007,858 | $21.5M | No change |
| PEPG Pepgen Inc. | 0.37% | 1,410,438 | $20.7M | New |
| RVMD Revolution Medicines Inc. | 0.35% | 618,885 | $19.9M | Reduce -24.4% |
| ABBV Abbvie Inc. | 0.34% | 106,500 | $19.4M | Reduce -55.3% |
| MLTX Moonlake Immunotherapeutics | 0.30% | 339,012 | $17.0M | Add +311.4% |
| ENGN Engene Holdings Inc. | 0.30% | 998,888 | $16.9M | New |
| LIVN Livanova PLC | 0.29% | 299,000 | $16.7M | New |
| ATHIRA PHARMA INC | 0.26% | 5,402,964 | $14.8M | No change |
| TCMD Tactile Systems Technology I | 0.26% | 903,085 | $14.7M | Add +27.7% |
| OBIO Orchestra Biomed Holdings Inc. | 0.24% | 2,545,881 | $13.4M | Add +4.7% |
| AXGN Axogen Inc. | 0.22% | 1,553,929 | $12.5M | Add +92.2% |
| EYPT Eyepoint Inc. | 0.21% | 589,646 | $12.2M | No change |
| ZYME Zymeworks Inc. | 0.20% | 1,074,807 | $11.3M | No change |
| RAPT THERAPEUTICS INC | 0.19% | 1,223,472 | $11.0M | Reduce -42.8% |
| TYRA Tyra Biosciences Inc. | 0.19% | 669,159 | $11.0M | Add +85.9% |
| PRCT Procept Biorobotics Corp. | 0.18% | 210,659 | $10.4M | New |
| MORF Morphic Holding Inc. | 0.18% | 288,221 | $10.1M | Add +405.8% |
| SPRY Ars Pharmaceuticals Inc. | 0.16% | 867,319 | $8.9M | New |
| ARQT Arcutis Biotherapeutics Inc. | 0.13% | 750,000 | $7.4M | New |
| AVBP Arrivent Biopharma Inc. | 0.13% | 415,000 | $7.4M | New |
| DTIL Precision Biosciences Inc. | 0.11% | 480,483 | $6.5M | New |
| COGT Cogent Biosciences Inc. | 0.10% | 883,333 | $5.9M | Reduce -21.3% |
| KALV Kalvista Pharmaceuticals Inc. | 0.10% | 500,000 | $5.9M | New |
| IBRX Immunitybio Inc. | 0.10% | 1,052,887 | $5.7M | New |
| MGNX Macrogenics Inc. | 0.10% | 378,327 | $5.6M | Reduce -38.2% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.09% | 500,000 | $5.2M | New |
| XFOR X4 Pharmaceuticals Inc. | 0.09% | 3,545,454 | $4.9M | No change |
| ESTA Establishment Labs Holdings | 0.07% | 82,299 | $4.2M | No change |
| NAMS Newamsterdam Pharma Co. NV | 0.07% | 175,000 | $4.1M | New |
| ABSI Absci Corp. | 0.07% | 700,000 | $4.0M | New |
| VERU Veru Inc. | 0.07% | 5,584,699 | $3.9M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.07% | 150,000 | $3.7M | New |
| TRINITY BIOTECH INVT LTD | 0.06% | 1,800,000 | $3.7M | New |
| NBTX Nanobiotix SA - ADR | 0.06% | 555,066 | $3.6M | No change |
| NVNO Envveno Medical Corporation | 0.06% | 623,315 | $3.4M | No change |
| RVNC Revance Therapeutics Inc. | 0.05% | 600,000 | $3.0M | New |
| FORTE BIOSCIENCES INC | 0.04% | 3,265,359 | $2.3M | No change |
| SINGULAR GENOMICS SYSTEMS IN | 0.02% | 2,126,893 | $1.1M | No change |
| KURA Kura Oncology Inc. | 0.02% | 48,200 | $1.0M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.01% | 300,000 | $852K | Reduce -84.0% |
| VBIVQ Vbi Vaccines Inc. | 0.01% | 1,261,710 | $757K | Reduce -8.7% |
Options reported separately and not counted above: IRON puts ($18.7M), AMLX calls ($4.8M), XBI puts ($4.7M), APLT calls ($3.4M), NVAX puts ($3.3M), IMVT calls ($3.2M), AGIO calls ($2.9M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $52K (not counted above)
Total filed on the 13F, all lines: $5.7B.
Portfolio Sells Q4 2023 → Q1 2024
| LIANY Lianbio-ADR | Sold out | 0.00% | −5.75 |
| CERE Cerevel Therapeutics Holding | Reduce -1.6% | 8.04% | −2.35 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −2.13 |
| NUVL Nuvalent Inc. Class A | Reduce -4.6% | 3.68% | −1.12 |
| RYZB Rayzebio Inc. | Sold out | 0.00% | −1.03 |
| RAPT THERAPEUTICS INC | Reduce -42.8% | 0.19% | −1.00 |
| ACLX Arcellx Inc. | Reduce -13.4% | 4.82% | −0.82 |
| BBIO Bridgebio Pharma Inc. | Reduce -19.3% | 0.77% | −0.81 |
| VRNA Verona Pharma Ltd. | Reduce -2.7% | 1.07% | −0.65 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -84.0% | 0.01% | −0.60 |
| CABA Cabaletta Bio Inc. | Reduce -14.3% | 0.52% | −0.50 |
| ABBV Abbvie Inc. | Reduce -55.3% | 0.34% | −0.48 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -18.9% | 0.68% | −0.46 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −0.37 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.35 |
| IRON Disc Medicine Inc. | Reduce -8.1% | 1.03% | −0.29 |
| TNGX Tango Therapeutics Inc. | Sold out | 0.00% | −0.25 |
| RVMD Revolution Medicines Inc. | Reduce -24.4% | 0.35% | −0.17 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.17 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.16 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.14 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.07 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.06 |
| KRON Kronos Bio Inc. | Sold out | 0.00% | −0.05 |
| COGT Cogent Biosciences Inc. | Reduce -21.3% | 0.10% | −0.04 |
| MGNX Macrogenics Inc. | Reduce -38.2% | 0.10% | −0.03 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −0.03 |
| VBIVQ Vbi Vaccines Inc. | Reduce -8.7% | 0.01% | −0.00 |
| CYPH Cypherpunk Technologies Inc. | Sold out | 0.00% | −0.00 |
| BCAB Bioatla Inc. | Sold out | 0.00% | −0.00 |
| NTRA Natera Inc. | Reduce -10.9% | 1.22% | +0.03 |
| SYRE Spyre Therapeutics Inc. | Reduce -1.9% | 1.71% | +0.46 |
Portfolio Buys Q4 2023 → Q1 2024
| IOVA Iovance Biotherapeutics Inc. | Add +60.9% | 5.03% | +2.86 |
| FUSN Fusion Pharmaceuticals Inc. | Add +148.1% | 2.56% | +1.97 |
| VKTX Viking Therapeutics Inc. | New | 1.44% | +1.44 |
| APGE Apogee Therapeutics Inc. | Add +12.7% | 2.41% | +1.27 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +184.4% | 2.02% | +1.24 |
| NBIX Neurocrine Biosciences Inc. | Add +197.1% | 1.96% | +1.16 |
| SLDB Solid Biosciences Inc. | Add +97.6% | 1.62% | +1.14 |
| ITCI Intra-Cellular Therapies Inc. | Add +877.2% | 1.29% | +1.11 |
| CGON CG Oncology Inc. | New | 1.01% | +1.01 |
| ATXS Astria Therapeutics Inc. | Add +62.0% | 1.61% | +0.92 |
| PRAX Praxis Precision Medicines I | New | 0.88% | +0.88 |
| PCVX Vaxcyte Inc. | Add +77.6% | 2.33% | +0.80 |
| APLT Applied Therapeutics Inc. | Add +96.2% | 0.96% | +0.65 |
| AORT Artivion Inc. | Add +186.6% | 1.00% | +0.62 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 0.61% | +0.61 |
| EWTX Edgewise Therapeutics Inc. | Add +317.5% | 0.75% | +0.61 |
| ARVN Arvinas Inc. | Add +249.2% | 0.90% | +0.57 |
| OCUL Ocular Therapeutix Inc. | New | 0.53% | +0.53 |
| IRTC Irhythm Holdings Inc. | New | 0.50% | +0.50 |
| EOLS Evolus Inc. | Add +45.2% | 1.42% | +0.49 |
| CELC Celcuity Inc. | Add +59.5% | 0.90% | +0.42 |
| MDT Medtronic PLC | Add +46.4% | 2.20% | +0.40 |
| SWTX Springworks Therapeutics Inc. | Add +15.6% | 1.96% | +0.37 |
| PEPG Pepgen Inc. | New | 0.37% | +0.37 |
| PTGX Protagonist Therapeutics Inc. | Add +159.4% | 0.51% | +0.31 |
| ISRG Intuitive Surgical Inc. | Add +85.1% | 0.72% | +0.30 |
| ENGN Engene Holdings Inc. | New | 0.30% | +0.30 |
| LIVN Livanova PLC | New | 0.29% | +0.29 |
| VRDN Viridian Therapeutics Inc. | Add +111.4% | 1.13% | +0.29 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +51.7% | 2.50% | +0.28 |
| SRPT Sarepta Therapeutics Inc. | Add +16.3% | 1.20% | +0.23 |
| AUTL Autolus Therapeutics PLC | Add +136.5% | 0.49% | +0.22 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +17.6% | 1.22% | +0.22 |
| MLTX Moonlake Immunotherapeutics | Add +311.4% | 0.30% | +0.19 |
| PRCT Procept Biorobotics Corp. | New | 0.18% | +0.18 |
| TMCI Treace Medical Concepts Inc. | Add +84.3% | 0.53% | +0.17 |
| SPRY Ars Pharmaceuticals Inc. | New | 0.16% | +0.16 |
| MORF Morphic Holding Inc. | Add +405.8% | 0.18% | +0.14 |
| ARQT Arcutis Biotherapeutics Inc. | New | 0.13% | +0.13 |
| AVBP Arrivent Biopharma Inc. | New | 0.13% | +0.13 |
| DTIL Precision Biosciences Inc. | New | 0.11% | +0.11 |
| AKRO Akero Therapeutics Inc. | Add +43.4% | 0.62% | +0.11 |
| KALV Kalvista Pharmaceuticals Inc. | New | 0.10% | +0.10 |
| IBRX Immunitybio Inc. | New | 0.10% | +0.10 |
| AXGN Axogen Inc. | Add +92.2% | 0.22% | +0.10 |
| BBOT Bridgebio Oncology Therapeut | New | 0.09% | +0.09 |
| TYRA Tyra Biosciences Inc. | Add +85.9% | 0.19% | +0.08 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.07% | +0.07 |
| ABSI Absci Corp. | New | 0.07% | +0.07 |
| KYTX Kyverna Therapeutics Inc. | New | 0.07% | +0.07 |
Options Activity Q4 2023 → Q1 2024
| IRON Disc Medicine Inc. | put | New | 300,000 | $18.7M |
| AMLX Amylyx Pharmaceuticals Inc. | call | New | 1,679,125 | $4.8M |
| XBI SS SPDR S&P Biotech ETF | put | Reduce -97.4% | 50,000 | $4.7M |
| NVAX Novavax Inc. | put | Reduce -50.0% | 700,000 | $3.3M |
| IMVT Immunovant Inc. | call | New | 100,000 | $3.2M |
| AGIO Agios Pharmaceuticals Inc. | call | New | 100,000 | $2.9M |
| EYPT Eyepoint Inc. | put | Sold out | 750,000 | $38Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $6.4B | PRAX, SYRE, CELC, ASND, RYTM |
| Q1 2026Amended | 89 | $5.0B | PRAX, CELC, ASND, ROIV, CNTA |
| Q4 2025 | 109 | $5.4B | PRAX, CELC, RYTM, ASND, APGE |
| Q3 2025 | 88 | $3.4B | RYTM, ASND, ACLX, CELC, NUVL |
| Q2 2025 | 80 | $2.7B | VRNA, ASND, ACLX, RYTM, NUVL |
| Q1 2025Amended | 84 | $2.8B | VRNA, ACLX, FOLD, EWTX, RYTM |
| Q4 2024 | 95 | $3.6B | VRNA, ACLX, FOLD, RYTM, NUVL |
| Q3 2024 | 99 | $4.7B | ACLX, NUVL, FOLD, IOVA, PCVX |
| Q2 2024Amended | 104 | $4.1B | CERE, FOLD, ACLX, IOVA, NUVL |
| Q1 2024Amended | 102 | $5.7B | CERE, FOLD, IOVA, ACLX, NUVL |